Bolt Biotherapeutics (BOLT) stock

Market cap $6.8MShares as of Aug 4

$3.51
+0.31%

After-hours. Prices 17 minutes old, as of 6:00 PM ET. Pro members see real-⁠time prices.

Not scored

Breakaway doesn't score BOLT. It is too small and too thinly traded for a fair Quality Score.

Healthcare · Biotech

Cash$18.1M, about 2 quarters at the last year's spendingOn Jun 30 · the company says “into first quarter 2027”

Follow BOLT's trial news. Pro members can get an alert when Bolt Biotherapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an optional alert when BOLT files news on its trialSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. 3,244 stocks are scored and ranked, every 15 seconds while the market is open. Pro members see it live.

Cash$18.1M, about 2 quarters at the last year's spendingOn Jun 30 · the company says “into first quarter 2027”

What's next for BOLT, and how long its cash lasts

From Bolt Biotherapeutics’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.

Its trials

A trial underway
First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal CancerPhase 1/2 · Recruiting · 122 people · main data estimated May 2027 · NCT06921837

For Pro members: 24 filings.

Cash runway Jun 30 balance sheet

About 2 quarters

$18.1M in cash and investments (the company's own count), at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money. The company's own estimate is “into first quarter 2027” (8-K, Aug 11).

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

No shelf registration of its own or at-the-market program on file in the last three years.

A shelf lets a company sell shares later; an at-the-market program sells them into the market over time. Neither is a sale by itself.

For Pro members: the amounts, and the share count against a year ago.

Insiders

Chief Operating Officer Grant Yonehiro sold 13,176 shares on Sep 18. 4 more insider trades this year.

From their own Form 4 filings: buys and sales in the market, not awards or shares withheld for tax.

For Pro members: every trade, and William Quinn’s 10 filings and quotes.

Get an optional alert when BOLT files news on its trialSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.

DateStockDrug

8 more FDA dates and 113 trial data dates in the next 60 days. Pro members see every one, with the cash against its date and an optional alert before it. Get in free →

BOLT's latest filings

12 more filings in the last year, for Pro members

From SEC EDGAR, as filed. Each opens the filing on the SEC's site.

Why BOLT isn't scored

The Quality Score reads US-listed stocks worth $50M or more that trade at $1 or more and 300,000 shares a day. BOLT is worth about $6.8M and trades about 39,000 shares a day. A stock that clears every mark is scored from the next weekly rebuild.

Straight Answers

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Where does the data come from?

Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.

Do I need an account?

Not to start. Tap any green button and you're in, free, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.

Is this investment advice?

No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.

The price on this page is delayed at least 15 minutes. The share count and the filings are shown as filed.